Neogenomics (NEO) Receivables (2010 - 2026)

Neogenomics (NEO) has 17 years of Receivables data on file, last reported at $175.6 million in Q2 2026.

• Quarterly Receivables rose 14.66% year-over-year to $175.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $175.6 million (up 14.66% YoY) and the FY2025 annual result came in at $159.2 million, up 5.71% from the prior year.
• Receivables grew to $175.6 million in Q2 2026, from $167.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $175.6 million in Q2 2026 to a low of $112.4 million in Q1 2022.
• A 5-year average of $140.2 million and a median of $143.5 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables rose 17.13% — and 2025, when it increased 2.55%.
• Tracing NEO's Receivables over 5 years: stood at $121.6 million in 2022, then gained by 7.94% to $131.3 million in 2023, then grew by 14.76% to $150.6 million in 2024, then climbed by 5.71% to $159.2 million in 2025, then rose by 10.25% to $175.6 million in 2026.
• The last three Receivables figures came in at $175.6 million (Q2 2026), $167.4 million (Q1 2026), and $159.2 million (Q4 2025), per Business Quant data.